Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sedation for gastroenteroscopy with remimazolam + etomidate combined with oliceridine or sufentanil
ChiCTR2400082452Phase 4Recruiting
- Sponsor
- Department of Anesthesiology and Perioperative Medicine, Qingdao Central Hospital
- Start
- Mar 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of remimazolam, etomidate, oliceridine and sufentanil in procedural sedation and analgesia (PSA) (2 arms), sponsored by Department of Anesthesiology and Perioperative Medicine, Qingdao Central Hospital. Primary endpoint: respiratory depression. Started Mar 2024; status: recruiting.
02
Drugs
remimazolametomidateoliceridinesufentanil
03
Conditions
procedural sedation and analgesia (PSA)
Beyond the preview
Go deeper on ChiCTR2400082452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082452.